explore -WSS

explore

author：hotspot 2025-09-06 03:33:22 - browse：8

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： NIH fellows want a pay raise. Will that mean less money for grants?

explore

WSS

Adults seen as increasingly susceptible to measles

Leqembi, other new Alzheimer’s drugs require better biomarkers

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Study: Pain burden is higher in Black NFL players than white ones

Why ADHD is under

The high personal cost of affirmative action for Black doctors

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

Apple is now the first public company to be valued at $3 trillion

The high personal cost of affirmative action for Black doctors

Moonlake's readout produced a cash windfall. Risks remain

EQRx, failed developer of low

Wildfire smoke exposes gaps in outdoor worker protections

What the US credit downgrade means for the economy, your finances

Jerome Adams on the need for new antivirals for Covid

Lecanemab for Alzheimer's is coming. Is the health system ready?

As demand for Covid shots wanes, Moderna seeks its next success

Why ADHD is under

leisure time

California’s proposed $25 per hour health care minimum wage

What the US credit downgrade means for the economy, your finances

Why ADHD is under

Beach reads and more: STAT's 2023 summer book list

Trump indictment: Who are the 'co

No plane should take off without an EpiPen onboard

explore

hotspot

focus

knowledge